CervoMed Inc. — Investor Relations & Filings

CervoMed Inc. is a clinical-stage biotechnology company that develops treatments for age-related neurologic disorders. The company focuses on neurodegenerative diseases, including Dementia with Lewy Bodies (DLB), Alzheimer's, and Huntington's disease. Its lead investigational candidate is neflamapimod, an orally administered, small molecule brain penetrant that inhibits the p38 alpha protein kinase. CervoMed's scientific approach is based on early intervention to reverse synaptic dysfunction, which is considered a reversible aspect of the neurodegenerative process, before the onset of irreversible nerve cell death. The company is advancing neflamapimod through clinical trials, including a Phase 2 study for patients with DLB.